- Business Wire•9 days ago
Acorda Therapeutics, Inc. will host a conference call and webcast to report its third quarter 2016 financial results and pipeline updates on Thursday, October 27 at 8:30 a.m.
- Business Wire•13 days agoData from Clinical and Preclinical Trials of CVT-301 for Treatment of OFF Periods in Parkinson’s Disease Published in Science Translational Medicine
Results from Phase 1, Phase 2a and preclinical studies of CVT-301, an inhaled form of levodopa, have been featured in the current edition of Science Translational Medicine. Acorda Therapeutics, Inc.
- Business Wire•14 days ago
Acorda Therapeutics, Inc. has been named as one of the 100 Best Medium Workplaces based on an independent survey by Fortune Magazine and Great Place to Work®. The survey included more than 52,000 employees at over 450 companies based in the United States.
Acorda Therapeutics, Inc. (ACOR)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||20.05 x 400|
|Ask||20.15 x 1400|
|Day's Range||19.50 - 20.15|
|52wk Range||18.78 - 43.63|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-148.52|
|Avg Vol (3m)||595,006|
|Dividend & Yield||N/A (N/A)|